Preclinical pharmacological studies with montelukast (Singulair), a selective cysteinyl leukotriene receptor (CysLT1) antagonist

Clinical and Experimental Allergy Reviews

Volumn 1, Issue 3, 2001, Pages 205-209

  Jones, T R ^a   Metters, K ^a   Evans, J ^b  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 28144460894     PISSN: 14729725     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-9725.2001.t01-1-00007.x     Document Type: Article

References (45)

1. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220:568-75.
2. Miller DK, Gillard JW, Vickers PJ et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990; 343:278-81.
3. Dixon RAF, Diehl RE, Opas E et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990; 343:282-4.
4. 4-receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992; 90:193-201.
5. 4-receptor antagonist. N Engl J Med 1990; 323:1739.
6. Dahlen B, Kumlin M, Johansson H et al. The leukotriene antagonist MK-0679 improves baseline pulmonary function and blocks aspirin-induced airway obstruction in aspirin-sensitive asthmatics. Am Rev Respir Dis 1992; 145:A15.
7. 4 antagonist, MK-0679. Am Rev Respir Dis 1993; 147:1442-6.
8. 4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 1992; 146:358-63.
9. 4-receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1991; 87:309 [abstract 677].
10. 4-receptor antagonist, in patients with chronic asthma. 8th International Conference on Prostaglandins, Rel Comps July 26-31, Montreal 163, abstract 639, 1992.
11. MacGlashan DW Jr, Schleimer RP, Peters SP et al. Generation of leukotrienes by purified human lung mast cells. J Clin Invest 1982; 70:747-51.
12. Williams JD, Czop JK, Austen KF. Release of leukotrienes by human monocytes on stimulation of their phagocytic receptor for particulate activators. J Immunol 1984; 132:3034-40.
13. 4. Proc Natl Acad Sci USA 1983; 80:7626-30.
14. 4 from alveolar macrophages. Nature 1982; 297:329-31.
15. Irvin CG, Tu YP, Sheller JR, Funk CD. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am J Physiol 1997; 272:L1053-L1058.
16. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Int Med 1994; 121:684-97.
17. Hay DWP, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci 1995; 16:304-9.
18. Chan CC, McKee K, Tagari P, Chee P, Ford-Hutchinson AW. Eosinophil-eicosanoid interactions: inhibition of eosinophil chemotaxis in vivo by a LTD4-receptor antagonist. Eur J Pharmacol 1990; 191:273-80.
19. Underwood DC, Osborn RR, Newsholme SJ, Torphy TJ, Hay DWP. Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: modulation by the LTD4 receptor antagonist pranlukast or an interleukin -5 monoclonal antibody. Am J Respir Crit Care Med 1996; 154:850-7.
20. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341:989-90.
21. Holgate ST, Sampson AP. Antileukotriene therapy: future directions. Am J Respir Crit Care Med 2000; 161:5147-S153.
22. Pizzichini E, Leff JA, Reiss TF et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999; 14:12-8.
23. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma: a multicenter, randomized double blind trial. Montelukast Clinical Research Study Group. Arch Intern.Med 1998; 158:1213-20.
24. Nakamura Y, Hoshino M, Simm JJ, Ishii K, Hosaka K, Sakamota T. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998; 53:835-41.
25. Laitinen LA, Laitinen A, Lindqvist A et al. Inhaled leukotriene E4 (LTE4) induces persistent eosinophilia and airway obstruction which is reversed by regular zafirluskast treatment. Eur Respir J 1999; 12:555.
26. Panettieri RA, Tan EM, Ciocca V, Luttmann MA, Leonard TB, Hay DW. Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 1998; 19:453-61.
27. Shoseyov D, Bibi H, Ofer S, Madar Z, Reifen R, Eliraz A. Montelukast prevents always remodeling in rats with chronic asthma. Am J Respir Crit Care Med 2000; 161:A742.
28. Henderson W, Chi EY. Leukotriene antagonist montelukast inhibits airway remodeling in a mouse asthma model. 11th International Congress on Advances in Prostaglandin Leukotriene Research, Florence June 4-8, 2000.
29. Coleman RA, Eglen RM, Jones RL et al. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv Prostaglandin Thromboxane Leukot Res 1995; 23:283-5.
30. Metters KM. Leukotriene receptors. J Lipid Med Cell Signal 1995; 12:413-27.
31. Ford-Hutchinson AW, Rodger IW. Receptor site blockers. In: Austen KF, Burakoff SJ, Rosen PS, Strom TB, eds. Therapeutic immunology. Boston: Blackwell, 1996:132-51.
32. Dahlèn S-E. Leukotriene receptors. Clin Rev Allergy Immunol 1999; 17:179-91.
33. Gorenne I, Norel X, Brink C. Cysteinyl leukotriene receptors in the human lung: what's new? Trends Pharmacol Sci 1996; 17:342-345.
34. Lynch KR, O'Neill GP, Liu Q et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399:789-93.
35. 2) receptor. J Biol Chem 2000; 275:14281-6.
36. Charette L, Jones TR, Gareau Y, Zamboni R. Antagonism of N-methyl leukotriene C4 (NMLTC4) induced contractions of guinea pig trachea: comparison to LTC4 (serine borate). 8th International Conference on Prostaglandins, Rel Comps, July 26-31, abstract 639, 1992.
37. 4 receptor antagonist. Can J Physiol Pharmacol 1995; 73:191-201.
38. 4 receptor antagonist (addendum). Can J Physiol Pharmacol 1996; 73:747.
39. Jones TR, Piechuta H, McAuliffe M et al. Comparative study of histamine, leukotriene D4 (LTD4) and acaris-induced changes in lung resistance (RL) in propofol (Rapinovet*). Anesthetized non-human primates. Naunyn Schmiedbergs Arch Pharmacol 1998; 358 (Suppl.1):R326.
40. Rodger IW. Leukotrienes, asthma and the preclinical science of montelukast. Eur Respir Rev 1998; 8:349-52.
41. Jones TR, Rodger IW. Role of leukotrienes and leukotriene receptor antagonists in asthma. Pulmon Pharmacol Ther 1999; 12:107-10.
42. Jones TR, McAuliffe M, McFarlane CS, Piechuta H, Macdonald D, Rodger IW. Effects of a selective phosphodiesterase 4 inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma. Can J Physiol Pharmacol 1998; 76:210-7.
43. Schoors DF, De Smet M, Reiss T et al. Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D-4 receptor antagonist, in healthy volunteers. Br J Clin Pharmacol 1995; 40:277-80.
44. Zhao JJ, Rogers JD, Holland SD et al. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos 1997; 18:769-77.
45. 4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101:834-46.